{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:38:07Z","timestamp":1788871087321,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GOG Statistical and Data Center","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ygyno.2010.12.358","type":"journal-article","created":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T04:34:01Z","timestamp":1296621241000},"page":"264-268","source":"Crossref","is-referenced-by-count":19,"title":["A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"121","author":[{"given":"Mark A.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"DeGeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Diane","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"VIII","key":"10.1016\/j.ygyno.2010.12.358_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"DuBois","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0010","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/bjc.1994.45","article-title":"Response of peritoneal solid tumours after intraperitoneal hemohyperthermia treatment with cisplatin or carboplatin","volume":"69","author":"Los","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2010.12.358_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1993.1171","article-title":"Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0035","first-page":"2373","article-title":"The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBDCA for advanced ovarian cancer patients","volume":"19","author":"Fujiwara","year":"1992","journal-title":"Gan To Kagaku Rvoho"},{"key":"10.1016\/j.ygyno.2010.12.358_bb0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Miyagi","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0045","first-page":"273","article-title":"The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors","volume":"30","author":"Liu","year":"1995","journal-title":"Chinese J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000011980","article-title":"A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer","volume":"56","author":"Polyzos","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2010.12.358_bb0060","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0070","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1525-1438.2005.15304.x","article-title":"Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube","volume":"15","author":"Fujiwara","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2010.12.358_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2010.12.358_bb0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810012655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810012655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T01:54:56Z","timestamp":1592272496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810012655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0090825810012655"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.358","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}